Optina Diagnostics news
Based on its recent analysis of the North American Hyperspectral Retinal Imaging Industry, Frost & Sullivan recognizes Optina Diagnostics with the 2022 Technology Innovation Leadership Award for offering sophisticated artificial intelligence (AI)-powered Retinal Deep Phenotyping™ solutions. Optina Diagnostics’ comprehensive technology facilitates early and non-invasive diagnostic tests for chronic diseases including neurodegenerative conditions with its highly differenti
Optina, an innovative diagnostics company, leader in retinal imaging, brain health and systemic disease detection, announces the closing of an up to
In fact, nearly 40% of people over the age of 65 suffer from some form of memory loss.
There’s currently no cure for Alzheimer’s or Alzheimer’s related dementia, early detection can give patients more control over how they manage their overall well-being. That includes managing their brain health to reduce certain risk factors, potentially delaying or
Optina Diagnostics announces today that it has signed an agreement with the Alzheimer Center Amsterdam, part of the Amsterdam University Medical Center to pursue the study of Optina’s Retinal Deep Phenotyping Platform™? in a cohort of 100 subjects. July 29, 2020
Optina Diagnostics announces today that it has signed an agreement with the Alzheimer Center Amsterdam, part of the Amsterdam University Medical Center to pursue the study of Optina’
Alzheimer’s awareness month, Optina Diagnostics and Wagner Macula Retina Center will Collaborate to Conduct a Clinical Study and Develop a Unique in-community Patient access Program Aimed to Identify the Causes of Memory Loss through Eye Diagnostics, November 6th 2019
Optina Diagnostics
Optina Diagnostics, a world leading company in retinal imaging and artificial intelligence with a vision to change mindsets when it comes to brain
Do you have senior moments? Are you concerned your memory loss may be a sign of something beyond normal aging? An innovative eye exam is helping physicians answer these questions with confidence.
Optina Diagnostics, a world leader in retinal imaging technology and AI with a vision to change mindsets when it comes to brain health and Dr. Jean-Claude Tardif’s research group from the Montreal Heart Institute, have partnered with the aim to develop a new biomarker for a
Optina Diagnostics announces today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its retinal imaging platform (CAPRS1/MHRC2). Optina Diagnostics’ platform uses Artificial Intelligence (AI) to analyze the data rich hyperspectral retinal images captured with the MHRC during a simple eye scan. Optina Diagnostics’ platform is intended for the detection of likely positron-emission to